REACT Study
Start date:Nov 2019 End date:
Dec 2019 Co-ordinated by:
Lumira Dx Main trial site:
RIE, Edinburgh
A performance evaluation study designed to assess the precision and accuracy of the Lumira DX point of care (POC) and C-Reactive (CRP) assay as an aid in the detection and evaluation of infection, tissue injury and inflammatory disorders.
In the emergency department (ED), CRP is tested in patients presenting with a variety of symptoms as an aid the detection and evaluation of infection, tissue injury or inflammatory disorders.
Primary objective – To determine the performance of the LumiraDx POC CRP assay when compared to the Siemens Dimension reference method in patients with symptoms of infection, tissue injury and inflammatory disorders.
Sample size – 50 participants over a duration of approximately 4 weeks.
Chief Investigator
Professor Alasdair Gray
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Local PI
Professor Alasdair Gray
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Research Team
Julia Grahamslaw
Lead Research Nurse
Nicky Freeman
Senior Research Nurse
More EMERGE Trials
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
TARGET-CTCA Trial
ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)
ATTEST2 Trial
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)